PMPRB report reveals most new medicines come to market with high treatment costs

Imported from official source

Announcement

Safety Classified by Officially

The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report.

August 22, 2023 — Ottawa, ON — Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report. The analysis finds that the number of new medicines launched in Canada is higher than the median for Organisation for Economic Co-operation and Development (OECD) countries but falls below the median of the eleven PMPRB comparators, all of which have lower average patented medicine prices according to the PMPRB’s Annual Report, 2021. Most new medicines come to market with high treatment costs, and specialty medicines such as biologic, orphan, and cancer treatments continue to make up a growing share of the new drug landscape.

The Meds Entry Watch report focuses on medicines approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada. This edition examines trends in the market for new medicines approved since 2016, highlighting the 50 medicines that received first-time market approval in 2020 and providing a preliminary analysis of the 55 medicines approved in 2021. The report also includes a section focused on medicines that were new to Canada in 2020 with an analysis of the rate of approvals per quarter over the past five years.

This publication informs decision makers, researchers, and patients of the evolving market dynamics of emerging therapies in Canadian and international pharmaceutical markets.

In 2020, 50 new medicines were approved by the FDA, the EMA, and/or Health Canada. Of those, 76% had high treatment costs (>$10,000 annually or >$5,000 per 28-day treatment cycle), 58% received an orphan designation, and 36% were oncology medicines.

This is an extract. The publication continues at the source.

Source: Patented Medicine Prices Review Board. Licence

Read the original at the source: https://www.canada.ca/en/patented-medicine-prices-review/news/2023/08/pmprb-report-reveals-most-new-medicines-come-to-market-with-high-treatment-costs.html

Officially imported this from Patented Medicine Prices Review Board’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Patented Medicine Prices Review Board — imported from official source
Official source
https://api.io.canada.ca/io-server/gc/news/en/v2?dept=patentedmedicinepricesreviewboard&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Patented%20Medicine%20Prices%20Review%20Board ATOM
Imported
October 03, 2026 20:43
Versions
1 recorded
Identity
https://www.canada.ca/en/patented-medicine-prices-review/news/2023/08/pmprb-report-reve...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.